Yupelri Availability: What Providers and Prescribers Need to Know in 2026

For clinicians managing patients with moderate-to-severe COPD who need nebulized bronchodilator therapy, Yupelri (revefenacin) fills an important clinical niche as the only once-daily nebulized LAMA approved in the United States. However, several access factors make it challenging to ensure consistent patient supply. This article reviews what prescribers need to know in 2026.

Current Yupelri Supply Status (2026)

Yupelri is not listed on the FDA Drug Shortage Database as of 2026. Manufactured by Viatris Specialty LLC, the product maintains consistent manufacturing and distribution. The availability challenge is not a supply disruption — it is a distribution and formulary access issue that affects patients' ability to obtain the drug at the retail level.

Revefenacin inhalation solution (175 mcg/3 mL unit-dose vials) is not routinely stocked at most community retail pharmacies due to low prescription volume and a WAC of $1,655.34 per 30-day supply. Specialty pharmacies and mail-order channels are more reliable dispensing pathways.

Clinical Indications and Patient Selection

Yupelri is FDA-approved for the maintenance treatment of COPD in adults. The primary clinical value of revefenacin over inhaler-based LAMAs is its nebulizer delivery, which is especially beneficial for:

Patients with physical limitations preventing proper coordination of dry powder or pressurized inhalers (e.g., severe arthritis, neurological conditions)

Patients with cognitive impairment who cannot reliably perform multistep inhaler technique

Elderly or frail patients who already use nebulized albuterol or ipratropium and benefit from consolidated nebulized regimens

Patients with severe COPD requiring high inspiratory flow rates that nebulizer delivery bypasses

Efficacy and Safety Summary

The efficacy of Yupelri is supported by two replicate 12-week Phase 3 placebo-controlled trials in 1,229 COPD patients, demonstrating statistically significant improvements in FEV1 versus placebo. A 52-week open-label active-controlled safety trial comparing Yupelri 175 mcg/day (n=335) with tiotropium 18 mcg/day (n=356) demonstrated a consistent safety profile comparable to tiotropium.

The most common adverse reactions (≥2%, more common than placebo) are cough, nasopharyngitis, upper respiratory tract infection, headache, and back pain. Clinically significant anticholinergic effects (urinary retention, narrow-angle glaucoma worsening) are possible and require appropriate patient screening.

Key Contraindications and Precautions to Document

Contraindicated: Known hypersensitivity to revefenacin or any product component

Not for acute use: Do not initiate in acutely deteriorating COPD. Not a rescue bronchodilator.

Hepatic impairment: Not recommended in any degree of hepatic impairment due to increased active metabolite exposure

OATP1B1/1B3 inhibitors: Cyclosporine, rifampicin, and ceftobiprole can significantly increase active metabolite exposure — coadministration not recommended

No concurrent anticholinergics: Do not co-prescribe other anticholinergics; additive effects increase risk of urinary retention, constipation, and glaucoma

Insurance Coverage and Prior Authorization Requirements

Yupelri is covered by Medicare Part B (80% reimbursement as a DME-administered nebulized medication), Medicare Advantage, and approximately 73% of commercial insurance plans. However, the majority of payers require prior authorization and step therapy.

UnitedHealthcare's 2026 criteria (effective 2/15/2026) require one of the following for initial approval:

Documented history of failure, contraindication, or intolerance to Spiriva HandiHaler or Respimat (tiotropium); OR

Documented inability to use a metered-dose, dry powder, or slow mist inhaler due to cognitive or physical impairment limiting coordination of handheld devices

When submitting prior authorization requests, ensure your documentation explicitly addresses one of these criteria. Inadequate documentation is the most common reason for initial denial.

Prescribing Tips for Smooth Yupelri Access

Send prescriptions to specialty pharmacies: Avoid sending Yupelri prescriptions to standard retail chain pharmacies, which rarely stock it. Direct prescriptions to a specialty pharmacy you trust.

Include J-code billing: Yupelri's HCPCS J-code is J7677. Medicare Part B billing uses this code, billed per microgram of revefenacin administered.

Document nebulizer medical necessity: Medicare Part B also covers durable medical equipment (DME) for nebulizers when medical necessity is documented.

Educate patients on the savings card: Commercially insured patients can pay as little as $0/month through the Yupelri Savings Card (up to 12 fills/year). Not available for Medicare/Medicaid patients.

How medfinder Supports Your Patients' Access

When patients struggle to locate Yupelri at their local pharmacy, medfinder.com/providers provides a structured solution. medfinder calls pharmacies in the patient's area to find which ones have Yupelri in stock and can fill the prescription, then texts results to the patient. This reduces abandonment and helps patients stay on their prescribed therapy. See the full provider guide: How to Help Your Patients Find Yupelri in Stock.